- Home
- GRAL
GRAL
GRAIL INC
as 11-21-2024 4:00pm EST
Stocks
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 449.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 603.0K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -63.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.33 - $23.36 | Next Earning Date: | 11-12-2024 |
| Revenue: | $117,669,000 | Revenue Growth: | 111.83% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest GRAIL INC News
GRAL Breaking Stock News: Dive into GRAL Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Grail Insider Sold Shares Worth $426,937, According to a Recent SEC Filing
PR Newswire
2 days ago
GRAIL to Participate in Upcoming Investor Conferences
MT Newswires
3 days ago
GRAIL Says First Person Tested With Blood-Based Assay in Lung Cancer Trial
PR Newswire
3 days ago
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
Insider Monkey
3 days ago
Is Illumina, Inc. (ILMN) the Best Immunotherapy Stock to Buy Now?
GuruFocus.com
7 days ago
GRAIL Inc (GRAL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...
Simply Wall St.
8 days ago
GRAIL Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
PR Newswire
9 days ago
GRAIL Reports Third Quarter 2024 Financial Results
Compare GRAL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GRAL GRAIL INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.